XOMA to Announce Second Quarter 2014 Financial Results and Host Webcast on August 7
July 30 2014 - 12:15PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of antibody therapeutics, announced the Company will
host a conference call on Thursday, August 7, 2014, at 4:30 p.m.
Eastern Daylight Time to discuss second quarter 2014 financial
results and provide an update on gevokizumab's global clinical
programs.
The webcast can be accessed via the Investors & Media
section of XOMA's website at http://investors.xoma.com/events.cfm
and will be available for replay until close of business on
November 7, 2014. Telephone numbers for the live audiocast are
877-369-6589 (U.S./Canada) and 408-337-0122
(international).
About XOMA Corporation
XOMA has built a portfolio of innovative therapeutic antibodies,
both in late-stage clinical development and in preclinical
research. XOMA focuses its antibody research and development
on allosteric modulation, which offers opportunities for new
classes of therapeutic antibodies to treat a wide range of human
diseases. XOMA's lead product candidate, gevokizumab (IL-1
beta modulating antibody), is in a global Phase 3 program in
non-infectious uveitis with its partner SERVIER and multiple
proof-of-concept studies in other IL-1-mediated
diseases. XOMA's scientific research also produced the XMet
program, which consists of three classes of preclinical antibodies,
including Selective Insulin Receptor Modulators (SIRMs) that could
have a major effect on the treatment of diabetes.
More detailed information can be found at www.xoma.com
CONTACT: XOMA Corporation
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2024 to May 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From May 2023 to May 2024